IL5 and asthma: Biologic agents such as omalizumab (anti-IgE), mepolizumab and benralizumab (anti-IL-5/IL-5R), and dupilumab (anti-IL-4Rα) are effective options for T2-high asthma, reducing exacerbations with good safety profiles.